Lv5
1210 积分 2021-02-19 加入
P2.10.10 Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery With Clinically Validated Tumor Selective Linker Payload
12天前
已完结
Development of Novel Antibody–Camptothecin Conjugates
12天前
已完结
Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
16天前
已完结
Preclinical Development of MGC028, an ADAM9-Targeted, Glycan-Linked, Exatecan-Based Antibody–Drug Conjugate for the Treatment of Solid Cancers
1个月前
已完结
A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors
1个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
1个月前
已完结
Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
1个月前
已完结
Abstract 4417: GS24-B025, a novel CDH17- and CEA-directed bispecific antibody-drug conjugate, for the treatment of colorectal cancer
1个月前
已关闭
Abstract A137: GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer
1个月前
已关闭
Computational optimization of antibody humanness and stability by systematic energy-based ranking
2个月前
已完结
皖公网安备34019202002308
